Project MOA Indication Exploratory research Preclinical Clinical study
Ph1 Ph2 Ph3

Direct renin inhibitor

  • Diabetic
    kidney disease
 
  • Hypertension
   

Enteropeptidase inhibitor

  • Obesity
  • Diabetes
 
  • Diabetic
    kidney disease
 

GPR40 full agonist

  • Obesity
  • Diabetes
  • NASH
   

GLP-1R/GIPR dual agonist

  • Obesity
  • Diabetes
     

Oral SSTR5 antagonist

  • Diabetes
  • Gallstones
  • Primary
    sclerosing
    cholangitis,
    etc
     

Not disclosed

  • Not disclosed
     

NRF2 activator

  • Chronic kidney
    disease
  • Diabetic kidney
    disease
  • NASH, etc.
     

The compound code starts with SCO-,
and is given to a compound to be used in a GLP study.

We are committed to building a portfolio of innovative
and sufficient R&D pipelines centered on the field of lifestyle-related diseases.

Our basic R&D strategy is to select different mechanism of action among projects at
each development stage, and to ensure that other compounds (backup compounds)
are considered in projects at the preclinical study stage,
which minimizes the development risk and
continuously enhances the drug candidate stage.

Process of drug discovery

Exploratory research

Selection of drug
discovery targets

Select the target (such as protein) for the drug to work.

Screening

Screen lead compounds as potential drug seeds according to the strength of binding to the target, toxicity, and other factors.

Lead compound optimization

Select the best compound after lead compounds are repeatedly converted.

Preclinical study

Pharmacology study

Lowest effective dose?

Pharmacokinetic study

How is it absorbed, distributed, metabolized, and excreted in the body?

General pharmacology study

How does it work in the body?

General toxicity study

Does it have strong toxicity or harmful effects?

Specific toxicity study

Does it have carcinogenicity or an effect on the fetus?

Investigational New Drug Application (IND)
Clinical study

Phase 1 study

Examine the safety in a small number of healthy volunteers.

Phase 2 study

Examine the efficacy and safety in a relatively small number of patients.
(Determine the dosing regimen, etc.)

Phase 3 study

Systematically examine whether a new drug candidate is worth developing in a large number of patients.

Marketing approval/launch